ALBIREO PHARMA - Stock Price History | ALBO

Historical daily share price chart and data for ALBIREO PHARMA since 2021 adjusted for splits. The latest closing stock price for ALBIREO PHARMA as of September 27, 2021 is 31.95.
  • The all-time high ALBIREO PHARMA stock closing price was 2998.20 on January 09, 2008.
  • The ALBIREO PHARMA 52-week high stock price is 43.41, which is 35.9% above the current share price.
  • The ALBIREO PHARMA 52-week low stock price is 27.23, which is 14.8% below the current share price.
  • The average ALBIREO PHARMA stock price for the last 52 weeks is 34.19.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ALBIREO PHARMA Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 27.8300 24.6300 42.1600 11.6700 37.5100 47.56%
2019 26.5328 24.1300 37.8600 16.9200 25.4200 3.63%
2018 31.2851 26.7800 39.3500 20.9000 24.5300 -4.18%
2017 22.8744 18.9900 28.1400 15.4800 25.6000 44.39%
2016 13.1431 9.6216 34.2800 7.0571 17.7300 72.33%
2015 27.6525 41.7417 50.4505 6.9069 10.2883 -74.24%
2014 65.2313 83.1832 103.3033 37.2372 39.9399 -42.17%
2013 97.2598 71.1712 170.2703 60.6607 69.0691 -2.13%
2012 81.1493 74.5465 102.7027 64.8649 70.5706 -5.33%
2011 187.7498 230.6306 330.3303 66.0661 74.5465 -66.09%
2010 466.8922 521.3213 687.0871 193.3934 219.8198 -57.83%
2009 558.7150 578.9790 714.7147 418.0180 521.3213 -9.96%
2008 1386.7180 2790.3904 2998.1982 224.6246 578.9790 -79.25%
2007 2165.9959 2162.1622 2802.4024 1733.3333 2790.3904 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.615B $0.008B
Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29